GSK: concludes string of agreements in Zantac litigation

(CercleFinance.com) - GSK announces that it has reached agreements with 10 law firms representing 93% of the pending Zantac (ranitidine) liability cases in US state courts.


GSK will pay up to $2.2bn to settle these cases, with implementation expected by the end of H1 2025.

In addition, an agreement in principle has been reached for a payment of $70m in respect of a 'qui tam' claim brought by Valisure.

GSK has admitted no liability and believes that these settlements are in the long-term interests of the company.


Copyright (c) 2024 CercleFinance.com. All rights reserved.